Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes

Zhu,Jia‑Jia; Chen,Yi‑Pu; Yang,Min; Liu,Bao‑Li; Dong,Jing; Dong,Hong‑Rui; Rui,Hong‑Liang; Cheng,Hong

doi:10.3892/mmr.2018.8386

Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes

Authors:
- Jia‑Jia Zhu
- Yi‑Pu Chen
- Min Yang
- Bao‑Li Liu
- Jing Dong
- Hong‑Rui Dong
- Hong‑Liang Rui
- Hong Cheng
View Affiliations

Affiliations: Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China
Published online on: January 5, 2018 https://doi.org/10.3892/mmr.2018.8386
Pages: 4589-4598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Obesity-related glomerulopathy (ORG) is morphologically characterized by glomerulomegaly with or without observable focal segmental glomerulosclerosis under light microscope, with decreased podocyte density and number, and with increased foot‑process width observed under electron microscope. The severity of podocyte injury is correlated with the degree of proteinuria and renal dysfunction. However, the pathogenesis of ORG is not well understood. The aim of the present study was to explore the possible pathogenic role of aldosterone (ALDO) in ORG. In the in vivo animal experiments, body weight, Lee's obesity index, abdominal fat index, urinary protein excretion, average glomerular diameter were significantly increased, the mRNA and protein expression of podocyte‑associated molecules including nephrin, podocin, podoplanin and podocalyxin were significantly reduced, and the Wnt/β‑catenin signaling pathway was activated in ORG model mice compared with the Control mice, whereas the administration of spironolactone significantly ameliorated these effects. In the in vitro experiments on cultured podocytes, the mRNA and protein expression levels of the aforementioned podocyte‑associated molecules were significantly downregulated and the Wnt/β‑catenin signaling pathway was activated following ALDO stimulation, whereas eplerenone significantly attenuated all the above effects. Dickkopf‑related protein 1 (DKK1), an inhibitor of Wnt/β‑catenin signaling pathway, also reduced the effects of ALDO exposure on the expression of podocyte‑associated molecules. The present study hypothesized that ALDO may be involved in the pathogenesis of ORG through the activation of Wnt/β‑catenin signaling pathway in podocytes.

View Figures

View References

1	Wang Y and Beydoun MA: The Obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: A systematic review and meta-regression analysis. Epidemiol Rev. 29:6–28. 2007. View Article : Google Scholar : PubMed/NCBI
2	Arroyo-Johnson C and Mincey KD: Obesity epidemiology worldwide. Gastroenterol Clin North Am. 45:571–579. 2016. View Article : Google Scholar : PubMed/NCBI
3	Wickman C and Kramer H: Obesity and kidney disease: Potential mechanisms. Semin Nephrol. 33:14–22. 2013. View Article : Google Scholar : PubMed/NCBI
4	Xie D and Bollag WB: Obesity, hypertension and aldosterone: Is leptin the link? J Endocrinol. 230:F7–F11. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hsu CY, McCulloch CE, Iribarren C, Darbinian J and Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med. 144:21–28. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kambham N, Markowitz GS, Valeri AM, Lin J and D'Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 59:1498–1509. 2001. View Article : Google Scholar : PubMed/NCBI
7	Cheng H, Chen YP, Zhang C, Fang J, Dong HR, Li WG and Zou WZ: Comparative study of clinicopathological features between two kinds of obesity-related glomerulopathy. Clin J Nephrol. 25:261–264. 2009.
8	D'Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M and Praga M: Obesity-related glomerulopathy: Clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 12:453–471. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW and Li LS: Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 48:772–779. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zoccali C and Mallamaci F: Obesity, diabetes, adiponectin and the kidney: A podocyte affair. Nephrol Dial Transplant. 23:3767–3770. 2008. View Article : Google Scholar : PubMed/NCBI
11	Camici M, Galetta F, Abraham N and Carpi A: Obesity-related glomerulopathy and podocyte injury: A mini review. Front Biosci (Elite Ed). 4:1058–1070. 2012.PubMed/NCBI
12	Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K and Fujita T: Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors. J Am Soc Nephrol. 17:3438–3446. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shibata S, Nagase M, Yoshida S, Kawachi H and Fujita T: Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension. 49:355–364. 2007. View Article : Google Scholar : PubMed/NCBI
14	Nagase M and Fujita T: Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 12:233–242. 2008. View Article : Google Scholar : PubMed/NCBI
15	Nagase M: Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol. 14:303–314. 2010. View Article : Google Scholar : PubMed/NCBI
16	Shibata S and Fujita T: Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Mol Cell Endocrinol. 350:273–280. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kato H, Gruenwald A, Suh JH, Miner JH, Barisoni-Thomas L, Taketo MM, Faul C, Millar SE, Holzman LB and Susztak K: Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 286:26003–26015. 2011. View Article : Google Scholar : PubMed/NCBI
18	Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB and Liu Y: Wnt/β-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 20:1997–2008. 2009. View Article : Google Scholar : PubMed/NCBI
19	Heikkilä E, Juhila J, Lassila M, Messing M, Perälä N, Lehtonen E, Lehtonen S, Sjef Verbeek J and Holthofer H: β-catenin mediates adriamycin-induced albuminuria and podocyte injury in the adult mouse kidneys. Nephrol Dial Transplant. 25:2437–2446. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zhou L and Liu Y: Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol. 11:535–545. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wang D, Dai C, Li Y and Liu Y: Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria. Kidney Int. 80:1159–1169. 2011. View Article : Google Scholar : PubMed/NCBI
22	Xiao L, Wang M, Yang S, Liu F and Sun L: A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy. Biomed Res Int. 2013:9870642013. View Article : Google Scholar : PubMed/NCBI
23	Li Z, Xu J, Xu P, Liu S and Yang Z: Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif. 46:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
24	He W, Kang YS, Dai C and Liu Y: Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 22:90–103. 2011. View Article : Google Scholar : PubMed/NCBI
25	Liu BL, Chen YP, Cheng H, Wang YY, Rui HL, Yang M, Dong HR, Han DN and Dong J: The Protective Effects of Curcumin on obesity-related glomerulopathy are associated with inhibition of Wnt/β-catenin signaling activation in podocytes. Evid Based Complement Alternat Med. 2015:8274722015. View Article : Google Scholar : PubMed/NCBI
26	Pei YY, Yang M, Zuo HL, Wang YY, Dong HR, Cheng H and Zuo ZZ: The establishment of obesity-related glomerulopathy mouse model. Chin J Integr Tradit West Nephrol. 15:110–113. 2014.(In Chinese).
27	Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K and Iida M: Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transpalnt. 26:2475–2484. 2011. View Article : Google Scholar
28	Huang H, You Y, Lin X, Tang C, Gu X, Huang M, Qin Y, Tan J and Huang F: Inhibition of TRPC6 signal pathway alleviates podocyte injury induced by TGF-β1. Cell Physiol Biochem. 41:163–172. 2017. View Article : Google Scholar : PubMed/NCBI
29	Ji ZZ and Xu YC: Melatonin protects podocytes from angiotensin II-induced injury in an in vitro diabetic nephropathy model. Mol Med Rep. 14:920–926. 2016. View Article : Google Scholar : PubMed/NCBI
30	Rebuffé-Scrive M, Surwit R, Feinglos M, Kuhn C and Rodin J: Regional fat distribution and metabolism in a new mouse model (C57BL/6J) of non-insulin-dependent diabetes mellitus. Metabolism. 42:1405–1409. 1993. View Article : Google Scholar : PubMed/NCBI
31	Wang XX, Ye T, Li M, Li X, Qiang O, Tang CW and Liu R: Effects of octreotide on hepatic glycogenesis in rats with high fat diet-induced obesity. Mol Med Rep. 16:109–118. 2017. View Article : Google Scholar : PubMed/NCBI
32	Li X, Yang J, Zhu Y, Liu Y, Shi X and Yang G: Mouse maternal high-fat intake dynamically programmed mRNA m⁶A modifications in adipose and skeletal muscle tissues in offspring. Int J Mol Sci. 17(pii): E13362016. View Article : Google Scholar : PubMed/NCBI
33	Oksay T, Yunusoğlu S, Calapoğlu M, Aydın Candan I, Onaran İ, Ergün O and Özorak A: Protective impact of resveratrol in experimental rat model of hyperoxaluria. Int Urol Nephrol. 49:769–775. 2017. View Article : Google Scholar : PubMed/NCBI
34	Cheng H, Dong HR, Lin RQ, Sun LJ and Chen YP: Determination of normal value of glomerular size in Chinese adults by different measurement methods. Nephrology (Carlton). 17:488–492. 2012. View Article : Google Scholar : PubMed/NCBI
35	Paller MS, Hoidal JR and Ferris TF: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 74:1156–1164. 1984. View Article : Google Scholar : PubMed/NCBI
36	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
37	Darouich S, Goucha R, Jaafoura MH, Zekri S, Ben Maiz H and Kheder A: Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis. Ultrastruct Pathol. 35:176–182. 2011. View Article : Google Scholar : PubMed/NCBI
38	Suwanpen C, Nouanthong P, Jaruvongvanich V, Pongpirul K, Pongpirul WA, Leelahavanichkul A and Kanjanabuch T: Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol. 29:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
39	Dinh Cat AN, Friederich-Persson M, White A and Touyz RM: Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 57:F7–F21. 2016. View Article : Google Scholar : PubMed/NCBI
40	Kawarazaki W and Fujita T: The role of aldosterone in obesity-related hypertension. Am J Hypertens. 29:415–423. 2016. View Article : Google Scholar : PubMed/NCBI
41	Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA and Bornstein SR: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 100:pp. 14211–14216. 2003; View Article : Google Scholar : PubMed/NCBI
42	Luther JM: Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 25:16–21. 2016. View Article : Google Scholar : PubMed/NCBI
43	Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, et al: Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: Implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 59:1069–1078. 2012. View Article : Google Scholar : PubMed/NCBI
44	Angers S and Moon RT: Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 10:468–477. 2009. View Article : Google Scholar : PubMed/NCBI
45	Gordon MD and Nusse R: Wnt signaling: Multiple pathways, multiple receptors and multiple transcription factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI
46	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI